Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 500 Shares of Stock

Posted by Brian Himes on Jun 12th, 2026

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director Jason Aryeh sold 500 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $250.00, for a total transaction of $125,000.00. Following the transaction, the director owned 107,080 shares of the company’s stock, valued at $26,770,000. The trade was a 0.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Jason Aryeh also recently made the following trade(s):

On Thursday, June 11th, Jason Aryeh sold 4,500 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $250.00, for a total transaction of $1,125,000.00.

Ligand Pharmaceuticals Stock Up 0.4%

NASDAQ LGND traded up $0.97 during mid-day trading on Friday, reaching $255.54. The stock had a trading volume of 247,086 shares, compared to its average volume of 221,643. Ligand Pharmaceuticals Incorporated has a 1 year low of $110.00 and a 1 year high of $259.03. The stock has a market cap of $5.12 billion, a PE ratio of 34.67, a price-to-earnings-growth ratio of 2.64 and a beta of 1.17. The company has a fifty day moving average price of $224.48 and a 200 day moving average price of $206.40. The company has a debt-to-equity ratio of 0.45, a current ratio of 21.28 and a quick ratio of 20.95.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $1.63 earnings per share for the quarter, missing analysts’ consensus estimates of $1.84 by ($0.21). Ligand Pharmaceuticals had a return on equity of 16.19% and a net margin of 55.95%.The firm had revenue of $51.72 million during the quarter, compared to analysts’ expectations of $59.10 million. During the same quarter in the previous year, the firm earned $1.33 earnings per share. Ligand Pharmaceuticals’s revenue was up 14.1% on a year-over-year basis. On average, research analysts expect that Ligand Pharmaceuticals Incorporated will post 4.47 earnings per share for the current year.

Institutional Investors Weigh In On Ligand Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Cim Investment Management Inc. grew its position in Ligand Pharmaceuticals by 3.4% in the 1st quarter. Cim Investment Management Inc. now owns 1,484 shares of the biotechnology company’s stock worth $296,000 after purchasing an additional 49 shares during the period. Maryland State Retirement & Pension System grew its position in Ligand Pharmaceuticals by 2.2% in the 4th quarter. Maryland State Retirement & Pension System now owns 2,872 shares of the biotechnology company’s stock worth $543,000 after purchasing an additional 61 shares during the period. Smartleaf Asset Management LLC grew its position in Ligand Pharmaceuticals by 31.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 271 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 65 shares during the period. CIBC Private Wealth Group LLC grew its position in shares of Ligand Pharmaceuticals by 86.3% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 69 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of Ligand Pharmaceuticals by 3.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 2,688 shares of the biotechnology company’s stock valued at $527,000 after acquiring an additional 78 shares during the period. Institutional investors own 91.28% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on LGND. Citigroup boosted their price objective on shares of Ligand Pharmaceuticals from $276.00 to $282.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Wall Street Zen lowered shares of Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. HC Wainwright boosted their price objective on shares of Ligand Pharmaceuticals from $243.00 to $289.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Royal Bank Of Canada lifted their target price on shares of Ligand Pharmaceuticals from $252.00 to $262.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Finally, Bank of America started coverage on shares of Ligand Pharmaceuticals in a research report on Wednesday, March 11th. They issued a “buy” rating and a $244.00 target price for the company. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $257.71.

View Our Latest Analysis on Ligand Pharmaceuticals

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.